InnoMedica's main focus is on the in-house development, manufacture, and production of medicines using the new nanotechnology. Many fundamentally effective active ingredients only reach the desired target site in the body in small quantities, and the treatment of diseases often leads to undesirable side effects in the body. InnoMedica has made it its aim to use its own nanotechnology and in-house production to combine active ingredients with the liposomal formulation and the nanocontainer in order to reach the target site in the body efficiently.
The technology platform can be used both for clinically established active ingredients, as in the case of InnoMedica's oncology product, and for new, tailored substances such as RNA or proteins. Several elements played a central role in the successful establishment of the nanotechnology platform. The company's own innovative manufacturing process for nanocarriers enables flexible production of the new drugs. Depending on the type of medical application and the target tissue in the body, both the lipid coating and the surface of the nanocarriers can be adapted. In addition to this potential for adapting the nanocarriers to a wide range of requirements, stability and replicability are of central importance in the design of the prototypes. Furthermore, the properties of the active ingredient used in combination with the design of the nanocarrier are taken into account in order to enable sufficient loading of the active ingredient.
